Effects of Huaiqihuang Granules adjuvant therapy in children with primary nephrotic syndrome

Zhou, Ping; Xiao, Qiu; Chen, Lan; Zou, Zhi-Jie; Wang, Yuqing; Zhu, Lin; Yu, Hui; Zhao, Chengguang; Wu, Yiling; Du, Xinying

doi:10.1515/biol-2019-0058

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with HSPN present high levels of IL-8, CCL2, TNF- α , IL-10, and IL-6 [ 23 , 24 ]. HQH administration elevates Treg and lowers Th17 levels [ 5 , 25 ]. Consistent with previous results, our study showed that Huaier acts on IL6, CCL2, IL-10, and TNF.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, glucocorticoid steroids combined with immunosuppressive therapy are recommended to treat HSPN [ 4 ]. However, clinical data suggest that this treatment has evident side effects such as gastrointestinal diseases, oncogenesis, and myelosuppression [ 5 ]. Therefore, it is necessary to identify new, effective, and safe strategies for the treatment of HSPN.…”

Section: Introductionmentioning

confidence: 99%

“…HQH is a traditional Chinese herbal formula, which comprises Trametes robiniophila Murr (Huaier), Polygonatum sibiricum (HJ), and Lycium barbarum (GQZ). HQH has been used as an adjuvant for primary nephropathy, mycoplasma pneumonia, and bronchial asthma in children [ 5 , 8 ]. HQH exhibits a significant therapeutic effect against kidney diseases by enhancing immune function and reducing proteinuria and hematuria [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Network Pharmacology and Molecular Docking Analysis to Explore the Mechanism of Huaiqihuang-Mediated Alleviation of Henoch–Schönlein Purpura Nephritis

Liu

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. Henoch–Schönlein purpura nephritis (HSPN) is considered a major cause of chronic renal failure and is the most common secondary glomerular disease in children. Huaiqihuang (HQH), a traditional Chinese herbal formula, exhibits therapeutic effects against HSPN in clinical practice. However, the potential molecular targets and mechanisms underlying HSPN treatment remain unclear. Methods. By constructing a protein-protein interaction (PPI) network, core targets related to HQH and HSPN were identified. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathways were analyzed to identify the main pathways related to HSPN based on the core targets. To screen the main active ingredients of HQH against HSPN, an ingredient-target-pathway network was constructed using the top 10 main pathways associated with HSPN. Then, molecular docking was performed to explore the interactions and binding patterns between molecules and proteins. Results. Clinical data showed that HQH combined with conventional medicine significantly reduced 24-hour urine protein excretion, urine microalbumin levels, and erythrocyte counts in the urine sediment of HSPN patients. By constructing PPI models, 15 potential core targets were identified. The top 10 main pathways showed higher enrichment ratios, including the cytokine–cytokine receptor interaction and signaling pathways related to NOD-like receptor, IL-17, etc. Through the ingredient-target-pathway network and molecular docking, we revealed that five active ingredients of HQH had good affinities with three core targets, AKT1, MMP9, and SERPINE1, which may be vital in treating HSPN. Conclusions. The study preliminarily explored the active ingredients, targets, and pathways involved in HQH therapy for HSPN. The mechanism of HQH therapy may be attributed to the modulation of inflammatory response, immune response, and oxidative stress. Combined with clinical data, our results indicate that HQH is highly effective in treating HSPN.

show abstract